ArticleThe American journal of managed care2021
Comparison of the use of the top-ranked cancer hospitals between Medicare Advantage and traditional Medicare.
Article in The American journal of managed care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 14 citations in OpenAlex.
- Quality, Cost, and Timeliness of Cancer Treatment in Medicare Advantage and Traditional Medicare.JAMA internal medicine · 2026Article
- Oncology Organization and Oncologist Networks Under Medicare Advantage Plans.JAMA network open · 2026Article
- Access to Specialty Cancer Care and Plan Disenrollment Among Medicare Beneficiaries.JAMA network open · 2026Article
- Medicare Insurance Type and Broad Genomic Profiling in Metastatic Cancer.JAMA network open · 2026Article
- State Medigap Policies and Disenrollment From Medicare Advantage Among Beneficiaries With Cancer.JCO oncology practice · 2026Article
- Delay in breast cancer surgery: evaluating patient, healthcare access, and social vulnerability predictors.Cancer causes & control : CCC · 2026Article
- Zero-premium Medicare Advantage plans: trends in areas with socioeconomic vulnerability and health needs.Health affairs scholar · 2025Article
- Medigap Regulations Provide Protections For Beneficiaries, Especially After Health Shocks, But May Raise Premiums.Health affairs (Project Hope) · 2025Article
- The effect of providing Medicare Advantage enrollees diagnosed with cancer additional time to reassess enrollment.Health affairs scholar · 2025Article
- Medigap Protection and Plan Switching Among Medicare Advantage Enrollees With Cancer.JAMA health forum · 2025Article
- Estimating financial and health burden by initial Medicare plan choice and history of cancer.Health affairs scholar · 2025Article
- Restrictiveness of Medicare Advantage provider networks across physician specialties.Health services research · 2024Article
- Medicare Advantage enrollment and outcomes of post-acute nursing home care among patients with dementia.Health affairs scholar · 2024Article
- Comparison of Financial Hardship and Healthcare Utilizations Associated with Cancer in the United States Medicare Programs during the COVID-19 Pandemic.Healthcare (Basel, Switzerland) · 2024Article
- Comparing Medicare plan selection among beneficiaries with and without a history of cancer.Health affairs scholar · 2024Article
- Medicare Advantage in Soft Tissue Sarcoma May Be Associated with Worse Patient Outcomes.Journal of clinical medicine · 2023Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectivesTo compare the use of top-ranked cancer hospitals for complex cancer surgery between Medicare Advantage (MA) and traditional Medicare fee-for-service (FFS) enrollees. STUDY
designCross-sectional analysis of Medicare claims and enrollment data.
methodsThe study used Medicare Provider Analysis and Review files to compare differences in use of top-ranked cancer hospitals for complex cancer surgery (lobectomy, esophagectomy, gastrectomy, colectomy, and the Whipple procedure [pancreaticoduodenectomy]) between MA and FFS enrollees 65 years and older who underwent the surgery in 2015 to 2017.
resultsAfter adjusting for demographic characteristics and county fixed effects, MA enrollees were less likely to use top-ranked cancer hospitals than FFS enrollees by 6.0 percentage points (95% CI, 4.7-7.2) overall; the difference varied from 3.5 percentage points (95% CI, 2.5-4.6) for colectomy to 14.3 percentage points (95% CI, 10.9-17.8) for the Whipple procedure. The difference in cancer surgery rate at a top-ranked cancer hospital between MA and FFS enrollees was larger for MA plans without out-of-network (OON) benefits (-7.5 percentage points; 95% CI, -9.1 to -5.9) than for MA plans with OON benefits (-2.3 percentage points; 95% CI, -2.9 to -1.7).
conclusionsMA enrollees were less likely to use top-ranked cancer hospitals for complex cancer surgery than FFS enrollees. This difference was larger for MA plans with more restrictive OON policies. These findings suggest that MA enrollees, particularly those with lower OON benefits, may have restricted access to top-ranked hospitals for cancer care compared with FFS enrollees.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.